SLC2A4 and diabetes mellitus: This is the first investigation with clear evidence that the OLE, as a potential insulin stimulator, can be used for the treatment of diabetes via the improvement of intracellular GLUT4 translocation in the skeletal muscle by the activation of Rab8A and Rab13 proteins.